Skip to main content

Search

Reset all filters
112 Result(s)
Sort by

Who we are

Who we are

The Boehringer Ingelheim Regional Center Vienna (RCV for short) bears business responsibility for more than 30 countries in Central and Eastern Europe and Central Asia.
Small Molecule Drug Discovery

Small Molecule Drug Discovery

Boehringer Ingelheim scientists continue to expand the horizons of what small molecule drugs can achieve.
Skin Diseases

Skin Diseases

Skin Diseases | We discover and develop breakthrough therapies that can be used to prevent, treat and repair many inflammatory and fibrotic diseases.
Drug discovery Boehringer Ingelheim

Drug discovery Boehringer Ingelheim

Every day, scientists at Boehringer Ingelheim embark on a journey. It is a journey that can take up to 15 years and requires significant investment. Only a tiny proportion of these journeys are successful.
Our Expectations

Our Expectations

We are committed to exemplary ethical and professional conduct both within the company and from our suppliers.
Cancer cell directed therapies

Cancer cell directed therapies

At Boehringer Ingelheim, we are investigating cancer cell directed therapies that target key cancer drivers and hallmarks to directly kill cancer cells.
Oncology Translational Science

Oncology Translational Science

Discover how Boehringer Ingelheim leverages translational science to bridge pre-clinical research and clinical development, enhancing patient outcomes in oncology. Learn about our patient-centric strategies, biomarker discovery, and collaborative efforts